AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1410729
Drug: ASL 900
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASL 900 mg and meperidine 100 mg/8 h (Group C)
Trial: 1410729
Drug: ASL 900
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASL 900 mg and 1.800 mg/8 h together with meperidine 100 mg/8 h (Group D)
Trial: 1410729
Drug: meperidine 50
RxNorm normalized name: meperidine 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meperidine 50 mg and 100 mg/8 h (Group G)
Trial: 1410729
Drug: meperidine 50
RxNorm normalized name: meperidine 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meperidine 50 mg and 100 mg/8 h together with ASL 1.800 mg/8 h (Group H)
Trial: 1410729
Drug: ASL 900
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASL 900 mg and 1.800 mg/8 h (Group A)
Trial: 1410729
Drug: ASL 900
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASL 900 mg and 3.600 mg/8 h (Group B)
Trial: 1410729
Drug: meperidine 50
RxNorm normalized name: meperidine 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meperidine 50 mg and ASL 1.800 mg/8 h (Group E)
Trial: 1410729
Drug: meperidine 50
RxNorm normalized name: meperidine 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meperidine 50 mg and ASL 3.600 mg/8 h (Group F)
Trial: 28967706
Drug: Letermovir 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letermovir 80 mg twice daily for 7 days with CsA 50 mg
Trial: 28967706
Drug: Letermovir 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letermovir 80 mg twice daily for 11 days with TAC 5 mg
Trial: 28967706
Drug: Letermovir 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letermovir 40 mg twice daily for 14 days with CsA 50 mg
Trial: 28967706
Drug: Letermovir 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letermovir 40 mg twice daily for 14 days with CsA 200 mg
Trial: 26484738
Drug: Robotic radiosurgery
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic radiosurgery (single-session, frameless, image-guided); tumor dose of 18-22 Gy (mean 20.3 Gy) prescribed to the 70% isodose line.
Trial: 22248392
Drug: Fluconazole 150
RxNorm normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 150 mg daily plus standard care
Trial: 22248392
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (surgical debridement + culture-specific antibiotics + offloading + glycaemic control)
Trial: 10513830
Drug: Perindopril 2
RxNorm normalized name: perindopril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 2 mg + Indapamide 0.625 mg (Per/Ind)
Trial: 10513830
Drug: Perindopril 2
RxNorm normalized name: perindopril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 2 mg + Indapamide 0.625 mg (Per/Ind) in ISH subgroup
Trial: 6181329
Drug: Endralazine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endralazine (10-20 mg t.i.d.)
Trial: 6181329
Drug: Dihydralazine (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydralazine (25-50 mg t.i.d.)
Trial: 30657853
Drug: Pembrolizumab 2
RxNorm normalized name: pembrolizumab 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 2 or 10 mg/kg Q3W
Trial: 26453968
Drug: Daclatasvir 30mg
RxNorm normalized name: DACLATASVIR 30MG TAB
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclatasvir 30mg plus simeprevir 150mg once daily without ribavirin
Trial: 26453968
Drug: Daclatasvir 30mg
RxNorm normalized name: DACLATASVIR 30MG TAB
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclatasvir 30mg plus simeprevir 150mg once daily with ribavirin
Trial: 22018509
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g DHA-rich fish oil
Trial: 22018509
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g EPA-rich fish oil
Trial: 22018509
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 g olive oil)
Trial: 7862879
Drug: Theobromine (560
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theobromine (560 mg)
Trial: 2492454
Drug: t‐PA (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t‐PA (1.5 mg/kg/4 hr) and heparin (10,000 units bolus)
Trial: 2492454
Drug: t‐PA (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t‐PA (1.5 mg/kg/4 hr) only
Trial: 2492454
Drug: t‐PA and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t‐PA and heparin
Trial: 1095107
Drug: Penicillin drugs
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin drugs (control group)
Trial: 31670790
Drug: Low-dose acupuncture
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acupuncture (DP)
Trial: 31670790
Drug: High-dose acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose acupuncture (DPTN)
Trial: 30623408
Drug: PAC‐14028 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAC‐14028 cream 0·1%
Trial: 30623408
Drug: PAC‐14028 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAC‐14028 cream 0·3%
Trial: 30623408
Drug: PAC‐14028 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAC‐14028 cream 1·0%
Trial: 26415793
Drug: 6, 8,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6, 8, 10, 12, or 14 mg intrathecal hyperbaric ropivacaine with 5 μg sufentanil
Trial: 22535635
Drug: Standard dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dialysis therapy with constant ultrafiltration (UF) rate, cool dialysate and high sodium conductivity (Treatment A)
Trial: 22535635
Drug: Dialysis regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysis regimens with adjunctive interventions including blood volume (BV) control (Treatment B)
Trial: 22535635
Drug: Dialysis regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysis regimens with the combination of BV and active blood temperature control (Treatment C)
Trial: 11106122
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (A, B, C)
Trial: 15978972
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate 160 mg/day
Trial: 15072869
Drug: Propionyl‐L‐carnitine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionyl‐L‐carnitine 2 g/day plus acetyl‐L‐carnitine 2 g/day
Trial: 2107926
Drug: Tacrine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine (mean of 114 mg daily) and lecithin (1200 mg daily)
Trial: 2107926
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and lecithin (1200 mg daily)
Trial: 30933384
Drug: 980‐nm diode
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 980‐nm diode laser (DL) irradiation in combination with mechanical therapy (setting 980 nm, 2.5 W, 10 kHz, pw, 30 s)
Trial: 29072018
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment using the Midnight-noon Ebb-flow method combined with syndrome differentiation for 3 months
Trial: 29072018
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment for language rehabilitation
Trial: 12057066
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon alfa-2b (HDI)
Trial: 12057066
Drug: Shorter courses
RxNorm normalized name: SALICYLIC ACID 2 mg in 100 mL TOPICAL SHAMPOO [FYENACEL CALMING SHOOTER CELLANDIR HAIR LOSS-Shampoo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shorter courses of HDI or vaccines
Trial: 12057066
Drug: Intermediate-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose interferon
Trial: 2562473
Drug: Inhaled ouabain
RxNorm normalized name: ouabain
DrugBank: Ouabain (DB01092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ouabain (doses ranged from 50 micrograms to 5000 micrograms)
Trial: 30500925
Drug: E-cigarette sampling
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E-cigarette sampling (weekly supply for 3 weeks)
Trial: 24166893
Drug: Calcium 2
RxNorm normalized name: docusate calcium 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 2 g
Trial: 24166893
Drug: Calcium 2
RxNorm normalized name: docusate calcium 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 2 g and Vitamin D3 800 IU/d
Trial: 11431615
Drug: Homeopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic treatment with APIS MELLIFICA 9 CH and BRYONIA 9 CH
Trial: 11431615
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment comprising naproxen and fluid restriction
Trial: 8039540
Drug: 300 ml
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ml grapefruit juice taken simultaneously with 10 mg coumarin
Trial: 8039540
Drug: 300 ml
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ml grapefruit juice taken 30 min prior to 10 mg coumarin
Trial: 8039540
Drug: coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: coadministration of grapefruit juice with 10 mg coumarin
Trial: 2646997
Drug: Epinephrine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (0.5 mg)
Trial: 2646997
Drug: Methoxamine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methoxamine (5 mg)
Trial: 30816640
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg subcutaneously Q6M
Trial: 30816640
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg orally QD
Trial: 18091268
Drug: Coiling treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coiling treatment
Trial: 18091268
Drug: Clipping treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clipping treatment
Trial: 16127299
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg phytosterols
Trial: 16127299
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg phytosterols
Trial: 16127299
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg phytosterols
Trial: 11908511
Drug: Short-acting beta2-agonist
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting beta2-agonist (salbutamol)
Trial: 11908511
Drug: Long-acting beta2-agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting beta2-agonist (formoterol)
Trial: 10452629
Drug: Fluconazole 200
RxNorm normalized name: fluconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 200 mg per week
Trial: 7606068
Drug: 3-L WBI
RxNorm normalized name: 3-(L-MENTHOXY)-2-METHYLPROPANE-1,2-DIOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-L WBI at 2 L/h
Trial: 7606068
Drug: 8-L WBI
RxNorm normalized name: 8-L-lysinevasopressin
DrugBank: Lypressin (DB14642)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-L WBI at 2 L/h
Trial: 2218650
Drug: Diet supplemented
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet supplemented with 20.4 g of psyllium daily
Trial: 21114174
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level nitrogen laser therapy along with antitubercular treatment (ATT)
Trial: 21114174
Drug: Chemotherapy (ATT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (ATT only)
Trial: 19281914
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg pretreatment >12 hours before coronary stenting
Trial: 19281914
Drug: Prasugrel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (60 mg loading dose, 10 mg/d maintenance dose)
Trial: 19281914
Drug: Clopidogrel 300
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300 mg loading dose administered at least 15 hours before elective PCI
Trial: 19281914
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg pretreatment before diagnostic catheterization
Trial: 19281914
Drug: Clopidogrel 300
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300 mg pretreatment before elective PCI
Trial: 12585987
Drug: Antioxidant vitamin
RxNorm normalized name: antioxidant vitamins with minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant vitamin supplements (vitamins E and C)
Trial: 10636510
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 or 150 mg/day)
Trial: 10636510
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (0.625 mg/day)
Trial: 27586249
Drug: linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin 5 mg for 4 weeks
Trial: 15801940
Drug: Ultramolecular homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultramolecular homeopathic medicines in C-30 potency administered twice weekly for 12 weeks
Trial: 1379969
Drug: Orgaran (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orgaran (loading dose of 1,000 anti‐Xa units intravenously followed by 750 anti‐Xa units subcutaneously 12‐hourly)
Trial: 1379969
Drug: Orgaran (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orgaran (750 anti‐factor Xa units subcutaneously 12‐hourly)
Trial: 1379969
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (5,000 units subcutaneously 12‐hourly)
Trial: 26554661
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy for 1 year
Trial: 23443441
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg once daily (n=213)
Trial: 21595575
Drug: Da-Cheng-Qi decoction
RxNorm normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Da-Cheng-Qi decoction (DCQD) administered for 7 days
Trial: 16705588
Drug: Protease inhibitor-based
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor-based treatment
Trial: 16705588
Drug: EFV-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EFV-based treatment
Trial: 11747870
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive preparations (three different marketed OC preparations)
Trial: 11747870
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive preparations (during treatment)
Trial: 8295815
Drug: Clarithromycin suspension,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin suspension, 7.5 mg/kg twice daily
Trial: 8295815
Drug: Penicillin VK
RxNorm normalized name: PENICILLIN VK 250MG TAB
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin VK suspension, 13.3 mg/kg three times per day
Trial: 27809637
Drug: BBT (anthocyanin-rich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBT (anthocyanin-rich black soybean testa extracts), 2.5 g/d
Trial: 27809637
Drug: Placebo (starch),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch), 2.5 g/d
Trial: 22696266
Drug: KN38-7271 high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KN38-7271 high-dose (1000 μg)
Trial: 22696266
Drug: KN38-7271 low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: KN38-7271 low-dose (500 μg)
Trial: 22696266
Drug: KN38-7271 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KN38-7271 (both doses)
Trial: 20683847
Drug: PEG‐IFN alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN alfa‐2b (1.5 μg/kg/week) plus RBV (800‐1,400 mg/day) for 48 weeks
Trial: 20683847
Drug: PEG‐IFN alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN alfa‐2b (1.5 μg/kg/week) plus RBV (800‐1,400 mg/day) for 72 weeks
Trial: 16393219
Drug: Senna (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senna (24 tablets of 12 mg, divided into two doses at 1 p.m. and 9 p.m.)
Trial: 16393219
Drug: PEG-ES (4-L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-ES (4-L standard solution)
Trial: 12482664
Drug: BBG2Na vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBG2Na vaccine
Trial: 9773734
Drug: Domperidone 20
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 20 mg q.i.d. (n=105)
Trial: 7921758
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral low-dose cyclophosphamide (CY) after failure of a monthly pulse regimen
Trial: 7921758
Drug: Monthly pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly pulse regimen of cyclophosphamide (CY)
Trial: 3078575
Drug: Oral whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral whole cell anti-ETEC vaccine (approx. 3 X 10(10) vaccine cells)
Trial: 25549482
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic dose adjusted based on intra-abdominal pressure (IAP)
Trial: 25549482
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic dose not adjusted based on IAP
Trial: 20420960
Drug: Brief course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief course in short‐wave diathermy treatment
Trial: 16150205
Drug: Tripterygium glycosides
RxNorm normalized name: anthraquinone glycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium glycosides tablet (TGT)
Trial: 16150205
Drug: Radix Tripterygium
RxNorm normalized name: Tripterygium wilfordii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radix Tripterygium hypoglaucum tablet (THT)
Trial: 355183
Drug: EMD 21657
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMD 21657 (3 x 300 mg for 6 weeks)
Trial: 19642992
Drug: Joint reminiscence
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint reminiscence groups held weekly for twelve consecutive weeks, followed by monthly maintenance sessions for a further seven months
Trial: 17049992
Drug: Lactitol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactitol (oral administration) in addition to standard medical treatment for 3 weeks
Trial: 17049992
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment (control group) for 3 weeks
Trial: 2893189
Drug: 10 fish-oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 fish-oil capsules ('MaxEPA') daily
Trial: 2893189
Drug: 10 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 placebo capsules (olive oil) daily
Trial: 31102045
Drug: Er,Cr:YSGG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er,Cr:YSGG laser preparation
Trial: 25148765
Drug: YKP10811 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YKP10811 10 mg
Trial: 25148765
Drug: YKP10811 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YKP10811 20 mg
Trial: 25148765
Drug: YKP10811 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YKP10811 30 mg
Trial: 24035957
Drug: Gabapentin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (300 mg) with methadone (40-120 mg)
Trial: 24035957
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with methadone (40-120 mg)
Trial: 21707911
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg twice-daily for 6 weeks
Trial: 21707911
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg daily for 6 weeks